Abstract
Intensifying systemic therapy improves outcomes in metastatic prostate cancer. As apalutamide and enzalutamide join abiraterone and docetaxel as treatment options for patients, the choice of therapy for individual patients becomes more complex. We anticipate precision targeted and immune therapies will build on the advances of recently completed large-scale trials.
Original language | English (US) |
---|---|
Pages (from-to) | 569-570 |
Number of pages | 2 |
Journal | Nature Reviews Urology |
Volume | 16 |
Issue number | 10 |
DOIs |
|
State | Published - Oct 1 2019 |
ASJC Scopus subject areas
- Urology